The GTSE1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the Jurkat human T lymphocyte cell line, carrying a targeted disruption of the GTSE1 gene. This polyclonal knockout model permits functional analysis of GTSE1 in a biologically relevant T-cell context without clonal selection artifacts. The heterogeneous editing events across the cell population provide a robust loss-of-function system for studying GTSE1-dependent processes.
The Jurkat cell line originates from an acute T cell leukemia patient and is widely employed as a model for T cell receptor signaling, apoptosis, and leukemogenesis. As CD4+ T lymphocytes, these cells recapitulate aspects of T-cell activation, cytokine production, and cell cycle progression. Their transformed nature and well-characterized signaling networks make them ideally suited for investigating oncogenic pathways and tumor suppressor mechanisms, particularly those involving the p53 tumor suppressor.
GTSE1 encodes a p53-inducible protein that negatively regulates p53 function and facilitates the G2/M transition of the cell cycle. It associates with microtubules and is essential for proper mitotic spindle assembly and chromosome segregation. Upstream, GTSE1 is transcriptionally activated by p53 and, in turn, modulates p53 stability and activity, creating an auto-regulatory loop. GTSE1 interacts with tubulin and microtubule-associated proteins, and its function integrates p53 signaling with cell cycle control. Downstream, GTSE1 influences microtubule stability and BAX-mediated apoptosis, while intersecting with core cell cycle regulators such as CDK1 and Cyclin B1.
In the context of Jurkat T cell leukemia, disruption of GTSE1 provides a valuable model to dissect the interplay between p53-dependent apoptosis and cell cycle progression. Given that p53 is often inactivated in T cell acute lymphoblastic leukemia, GTSE1 knockout cells may exhibit altered sensitivity to DNA-damaging agents like etoposide, revealing therapeutic vulnerabilities. This model thereby enables detailed investigation of how GTSE1 coordinates mitotic entry with cell survival signals in malignant T cells.
Researchers can employ the GTSE1 Knockout Jurkat Polyclonal Cells in a range of experimental settings, including western blotting to assess protein expression changes, flow cytometry for cell cycle distribution analysis, and immunofluorescence microscopy to visualize microtubule organization and mitotic spindle defects. Annexin V apoptosis assays combined with drug treatments (e.g., etoposide) allow evaluation of GTSE1??s role in p53-mediated cell death. Furthermore, RT-qPCR can quantify alterations in downstream targets like BAX and cell cycle regulators. These applications support studies of G2/M checkpoint regulation, microtubule dynamics, and targeted therapies in T-cell leukemia. For further information, please contact Ascent Research.
